CRISPR Therapeutics (CRSP) Competitors $38.95 +0.14 (+0.36%) Closing price 04:00 PM EasternExtended Trading$38.44 -0.52 (-1.32%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRSP vs. MRNA, EXEL, NBIX, QGEN, TECH, HALO, RGEN, RVMD, KRYS, and ADMAShould you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Moderna (MRNA), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Qiagen (QGEN), Bio-Techne (TECH), Halozyme Therapeutics (HALO), Repligen (RGEN), Revolution Medicines (RVMD), Krystal Biotech (KRYS), and ADMA Biologics (ADMA). These companies are all part of the "biological products, except diagnostic" industry. CRISPR Therapeutics vs. Moderna Exelixis Neurocrine Biosciences Qiagen Bio-Techne Halozyme Therapeutics Repligen Revolution Medicines Krystal Biotech ADMA Biologics CRISPR Therapeutics (NASDAQ:CRSP) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation. Is CRSP or MRNA more profitable? Moderna has a net margin of -110.04% compared to CRISPR Therapeutics' net margin of -981.54%. CRISPR Therapeutics' return on equity of -18.46% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-981.54% -18.46% -15.79% Moderna -110.04%-28.74%-21.83% Do analysts recommend CRSP or MRNA? CRISPR Therapeutics currently has a consensus price target of $73.11, indicating a potential upside of 87.69%. Moderna has a consensus price target of $58.70, indicating a potential upside of 123.70%. Given Moderna's higher probable upside, analysts clearly believe Moderna is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 1 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.48Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Which has more volatility & risk, CRSP or MRNA? CRISPR Therapeutics has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, Moderna has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500. Does the media refer more to CRSP or MRNA? In the previous week, Moderna had 10 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 26 mentions for Moderna and 16 mentions for CRISPR Therapeutics. Moderna's average media sentiment score of 1.02 beat CRISPR Therapeutics' score of 0.92 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 16 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in CRSP or MRNA? 69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by insiders. Comparatively, 11.0% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer CRSP or MRNA? CRISPR Therapeutics received 266 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 64.48% of users gave CRISPR Therapeutics an outperform vote while only 53.75% of users gave Moderna an outperform vote. CompanyUnderperformOutperformCRISPR TherapeuticsOutperform Votes48164.48% Underperform Votes26535.52% ModernaOutperform Votes21553.75% Underperform Votes18546.25% Which has stronger valuation & earnings, CRSP or MRNA? CRISPR Therapeutics has higher earnings, but lower revenue than Moderna. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$35M95.45-$366.25M-$4.37-8.91Moderna$3.20B3.17-$3.56B-$9.28-2.83 SummaryModerna beats CRISPR Therapeutics on 10 of the 19 factors compared between the two stocks. Remove Ads Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRSP vs. The Competition Export to ExcelMetricCRISPR TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.34B$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.33%P/E Ratio-8.9130.9821.8117.82Price / Sales95.45440.40379.3794.59Price / CashN/A168.6838.1534.64Price / Book1.733.486.464.00Net Income-$366.25M-$72.06M$3.20B$247.23M7 Day Performance24.56%9.29%6.63%7.25%1 Month Performance-7.53%-17.01%-8.50%-6.24%1 Year Performance-33.67%-29.24%10.47%-0.17% CRISPR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRSPCRISPR Therapeutics3.0286 of 5 stars$38.95+0.4%$73.11+87.7%-36.0%$3.34B$35M-8.91473MRNAModerna4.259 of 5 stars$25.18+0.3%$59.00+134.3%-74.5%$9.79B$3.20B-2.733,900Gap DownEXELExelixis4.2541 of 5 stars$34.81+0.7%$37.59+8.0%+56.7%$9.76B$2.17B19.711,220Positive NewsNBIXNeurocrine Biosciences4.8394 of 5 stars$92.50-3.3%$163.52+76.8%-29.5%$9.25B$2.36B28.191,200Analyst UpgradeNews CoveragePositive NewsGap UpQGENQiagen3.483 of 5 stars$40.25+5.2%$47.71+18.5%+8.3%$8.97B$1.98B112.396,030TECHBio-Techne4.8994 of 5 stars$52.32+1.2%$81.25+55.3%-21.3%$8.30B$1.20B53.043,100Positive NewsHALOHalozyme Therapeutics4.3932 of 5 stars$59.35-0.7%$62.78+5.8%+59.0%$7.35B$1.02B17.34390Positive NewsRGENRepligen4.7422 of 5 stars$115.99+3.6%$178.64+54.0%-25.8%$6.53B$634.44M-227.982,020Positive NewsRVMDRevolution Medicines3.816 of 5 stars$31.15-0.5%$65.23+109.4%+1.1%$5.78B$742,000.00-8.66250Positive NewsKRYSKrystal Biotech4.6447 of 5 stars$166.32-2.9%$220.00+32.3%-2.7%$4.80B$290.52M55.74210ADMAADMA Biologics1.8854 of 5 stars$18.32+1.7%$22.50+22.8%+247.3%$4.36B$426.45M65.88530Options VolumeNews CoveragePositive NewsGap Up Remove Ads Related Companies and Tools Related Companies Moderna Alternatives Exelixis Alternatives Neurocrine Biosciences Alternatives Qiagen Alternatives Bio-Techne Alternatives Halozyme Therapeutics Alternatives Repligen Alternatives Revolution Medicines Alternatives Krystal Biotech Alternatives ADMA Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRSP) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRSP Stock Free CRSP Stock Alerts